A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial.
Naoki IzawaToshiki MasuishiNaoki TakahashiHirokazu ShojiYoshiyuki YamamotoToshihiko MatsumotoKeiji SugiyamaTakeshi KajiwaraKentaro KawakamiNaoki AomatsuChihiro KondohHisato KawakamiNaoki TakegawaTaito EsakiMototsugu ShimokawaKazuto NishioYukiya NaritaHiroki HaraYu SunakawaNarikazu BokuToshikazu MoriwakiTakako Eguchi NakajimaKei MuroPublished in: Targeted oncology (2023)
FTD/TPI plus cetuximab rechallenge did not demonstrate clinically meaningful efficacy in all mCRC patients, but might be beneficial for the molecularly selected population.
Keyphrases
- wild type
- metastatic colorectal cancer
- end stage renal disease
- small cell lung cancer
- newly diagnosed
- ejection fraction
- prognostic factors
- clinical trial
- chronic kidney disease
- epidermal growth factor receptor
- open label
- squamous cell carcinoma
- tyrosine kinase
- phase iii
- randomized controlled trial
- locally advanced
- radiation therapy
- patient reported
- rectal cancer
- phase ii